More Articles Back to Article
Partnership to advance SARS-CoV-2 vaccine in Japan
MediciNova has signed a SARS-CoV-2 vaccine development deal that will use BC-PIV, a human parainfluenza virus type 2 vector created by BioComo and Mie University, with MediciNova gaining exclusive rights to global development of the vaccine. Seeking Alpha (free registration) (7/27)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!